Effectiveness of piracetam in cortical myoclonus

Movement Disorders

Volumn 8, Issue 1, 1993, Pages 63-68

  Brown, P ^a   Steiger, M J ^a   Thompson, P D ^a   Rothwell, J C ^a   Day, B L ^a   Salama, M ^b   Waegemans, T ^c   Marsden, C D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Crc ^*  (Belgium)

^c UCB PHARMA   (Belgium)

Author keywords

Cortical myoclonus; Piracetam

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; ISOCARBOXAZID; PHENYTOIN; PIRACETAM; PLACEBO; PRIMIDONE; TRYPTOPHAN; VALPROIC ACID;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; FEMALE; FUNCTIONAL DISEASE; HEADACHE; HUMAN; MALE; MOTOR PERFORMANCE; MYOCLONUS; ORAL DRUG ADMINISTRATION; SEIZURE; SORE THROAT; TASK PERFORMANCE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WRITING;

ADULT; AGED; ANTICONVULSANTS; CEREBRAL CORTEX; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROENCEPHALOGRAPHY; EPILEPSIES, MYOCLONIC; EVOKED POTENTIALS, SOMATOSENSORY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PIRACETAM;

EID: 0027395737     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.870080112     Document Type: Review

References (16)

1. Clinical, biochemical and physiological features distinguishing myoclonus responsive to 5‐hydroxytryptophan, tryptophan with monoamine oxidase inhibitor, and clonazepam
2. The treatment of severe action myoclonus
3. Effect therapeutique du piracetam dans un cas de myoclonies d'action post‐anoxique
4. Myoclonies d'intention et d'action postanoxiques: amelioration par le piracetam
5. Management of a case of myoclonia
6. New drugs for posthypoxic action myoclonus: observations from a well studies case
7. Antimyoclonic action of piracetam
8. Piracetam in the treatment of different types of myoclonus
9. Therapeutic trial with glycine in myoclonus
10. The two‐period cross‐over clinical trial
11. A metric for the evaluation of change in clinical trials
12. Biochemistry and therapeutics of posthypoxic myoclonus
13. Measurement of GABA in biological fluids: effect of GABA transaminase inhibitors
14. Decrease of GABA in the cerebrospinal fluid of patients with progressive myoclonus epilepsy and its correlation with the decrease of 5HIAA and HVA
15. Effects de substances stimulantes, sedatives, et hypnotiques sur les taux d'aminoacides cerebrales libres chez le rat
16. Piracetam: physiological disposition and mechanism of action